On hearing that the European Commission had on 28 May 2018 adopted a proposal for a Regulation to amend Regulation (EC) 469/2009 concerning the supplementary protection certificate (SPC) for medicinal products, many practitioners might have been forgiven for imagining that such proposal sought to deal with what are to them are the most pressing issues with the SPC Regulation—perhaps by seeking to introduce a unitary SPC to accompany the proposed unitary patent, or perhaps by addressing some of the confusion surrounding certain aspects of the SPC Regulation that has led to so many references to the Court of Justice but has resulted in so little clear guidance from that body.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
14 August 2026 Pressure for generic manufacturers of the blockbuster heart drug Entresto is mounting as the Swiss pharma company secures a win over a challenge to its UK patent protection.
11 August 2026 A litigation campaign against generic drugmakers, including Sandoz, Hikma, and Amenal, raise the stakes in the fight over two of the world’s most lucrative weight loss and diabetes treatments.
10 August 2026 Takanori Abe of Abe & Partners brings the perspective of a lawyer with first-hand experience in the German courtrooms to Pharmaceutical, Biological and Chemical Patents, a valuable resource on case law.